|
KMID : 0370920120290010001
|
|
Yeungnam Univercity Journal of Medicine
2012 Volume.29 No. 1 p.1 ~ p.8
|
|
|
Efficacy of Pneumococcal Vaccines
|
|
Park Ho-Sun
|
|
|
Abstract
|
|
|
|
Streptococcus pneumonia is a very important pathogen for children and elderly people. Two types of pneum- ococcal vaccines are available in the market: pneumococcal polysaccharide vaccine(PPSV) and pneumo- coccal conjugate vaccine(PCV). PPSVs have been used for more than 30 years, and PCVs for about 10 years. There have been many reports concerning the evaluation of the vaccines’ efficacies in preventing pneumo- coccal diseases such as meningitis, pneumonia, and otitis media and bacteremia, but the clinical trials had been performed with different conditions, such as diverse vaccine valencies, age groups, races, target out- comes, immunological cut-off values, and follow-up periods. PPSV is recommended for elderly people and chronic disease patients such as asthma, diabetes mellitus, chronic renal failure, and hyposplenic patients. According to the data from several systemic reviews and population-based surveillances, PPSV is effective for pneumococcal pneumonia and vaccine-type bacteremia among healthy adults. Until now, however, there is insufficient evidence of the effectiveness of PPSV among high-risk adults. PCV is very effective in preventing vaccine-type invasive pneumococcal disease(IPD) among children, but its efficacy for pneumonia is very low among children. The incidence of vaccine-related or non-vaccine-type IPDs is increasing after the introduction of 7-valent PCV(PCV7) as a routine immunization for children. Recently, 10- and 13-valent PCVs have been used for children, instead of PCV7. Therefore, continuous surveillance for serotype change among pneumococcal diseases is necessary to evaluate the vaccines’ efficacy.
|
|
|
KEYWORD
|
|
|
Pneumococcal vaccine, Efficacy, Systemic review
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|